Loading...
XSTOBIOG B
Market cap972mUSD
Dec 23, Last price  
110.20SEK
1D
0.64%
1Q
-1.34%
Jan 2017
83.67%
Name

Biogaia AB

Chart & Performance

D1W1MN
XSTO:BIOG B chart
P/E
29.40
P/S
8.28
EPS
3.75
Div Yield, %
2.73%
Shrs. gr., 5y
3.10%
Rev. gr., 5y
11.81%
Revenues
1.30b
+17.44%
40,438,00059,606,00086,792,000106,580,000145,190,000203,461,000236,033,000314,992,000645,252,000315,875,000481,802,000483,241,000534,696,000615,003,000741,870,000768,348,000747,077,000785,111,0001,103,958,0001,296,506,000
Net income
365m
-2.25%
23,250,000-19,825,0002,720,00019,659,00036,121,00036,045,00047,168,00076,369,000326,970,00061,722,000147,406,000121,408,000227,568,000180,564,000214,890,000187,347,000179,730,000196,273,000373,773,000365,352,000
CFO
426m
+33.56%
22,989,000-9,969,000-831,0005,088,00019,204,00053,290,00068,965,00072,792,000335,557,00078,441,000124,383,000117,501,000147,929,000222,615,000183,120,000147,855,000221,256,000221,875,000318,943,000425,965,000
Dividend
May 08, 20245 SEK/sh
Earnings
Feb 12, 2025

Profile

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylori–the gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.
URL
https://sv.biogaia.com/
IPO date
Jan 01, 1998
Employees
215
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,296,506
17.44%
1,103,958
40.61%
785,111
5.09%
Cost of revenue
855,597
769,449
542,611
Unusual Expense (Income)
NOPBT
440,909
334,509
242,500
NOPBT Margin
34.01%
30.30%
30.89%
Operating Taxes
103,482
73,840
56,439
Tax Rate
23.47%
22.07%
23.27%
NOPAT
337,427
260,669
186,061
Net income
365,352
-2.25%
373,773
90.44%
196,273
9.20%
Dividends
(292,849)
(301,331)
(68,870)
Dividend yield
Proceeds from repurchase of equity
(417)
(428)
(3,002)
BB yield
Debt
Debt current
8,800
20,088
10,400
Long-term debt
35,156
20,926
20,213
Deferred revenue
(4,913)
(9,813)
Other long-term liabilities
91,932
64,005
109,493
Net debt
(1,528,249)
(1,473,145)
(1,476,296)
Cash flow
Cash from operating activities
425,965
318,943
221,875
CAPEX
(48,568)
(17,916)
(6,379)
Cash from investing activities
(50,935)
(18,141)
(126,967)
Cash from financing activities
(308,421)
(313,588)
(81,846)
FCF
269,702
243,209
139,880
Balance
Cash
1,544,192
1,488,366
1,484,680
Long term investments
28,013
25,793
22,229
Excess cash
1,507,380
1,458,961
1,467,653
Stockholders' equity
876,967
818,624
723,386
Invested Capital
1,254,109
1,212,150
1,266,016
ROIC
27.36%
21.04%
15.26%
ROCE
20.54%
16.37%
12.10%
EV
Common stock shares outstanding
100,982
100,982
100,982
Price
Market cap
EV
EBITDA
466,190
358,399
269,741
EV/EBITDA
Interest
809
5,386
1,132
Interest/NOPBT
0.18%
1.61%
0.47%